NASDAQ:ABUS - Arbutus Biopharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.91 -0.09 (-4.50 %)
(As of 05/24/2019 04:00 PM ET)
Previous Close$1.91
Today's Range$1.90 - $2.02
52-Week Range$1.90 - $12.60
Volume261,131 shs
Average Volume257,123 shs
Market Capitalization$108.58 million
P/E RatioN/A
Dividend YieldN/A
Beta1.61
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. Its HBV product pipeline consists of AB-506, a capsid inhibitor that has shown improved potency and pharmacokinetics over its first generation capsid inhibitor; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach to treating disease. Its RNAi HBV candidates are designed to reduce hepatitis B surface antigen expression in patients chronically infected with HBV. The company develops AB-729, a second generation RNAi therapeutic targeted to hepatocytes; HBV RNA destabilizer AB-452, an orally administered agent, in pre-clinical studies in destabilizing HBV RNA, which leads to RNA degradation and to reduction in HBsAg levels. In addition, it engages conducting a Phase 1a/1b clinical trial and several pre-clinical and investigational new drug-enabling studies to evaluate proprietary HBV therapeutic agents, together with SOC therapies, and in combination with each other. The company has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; Acuitas Therapeutics Inc.; Alexion Pharmaceuticals Inc.; Monsanto Company; Marina Biotech, Inc.; and Arcturus Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.

Receive ABUS News and Ratings via Email

Sign-up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ABUS
CUSIPN/A
Phone604-419-3200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.90 million
Book Value$0.92 per share

Profitability

Net Income$-57,060,000.00
Net Margins-1,237.92%

Miscellaneous

Employees79
Market Cap$108.58 million
Next Earnings Date8/1/2019 (Estimated)
OptionableOptionable

Arbutus Biopharma (NASDAQ:ABUS) Frequently Asked Questions

What is Arbutus Biopharma's stock symbol?

Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."

How were Arbutus Biopharma's earnings last quarter?

Arbutus Biopharma Corp (NASDAQ:ABUS) released its quarterly earnings data on Monday, May, 6th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.31) by $0.16. The biopharmaceutical company had revenue of $0.70 million for the quarter, compared to analysts' expectations of $1.18 million. Arbutus Biopharma had a negative return on equity of 95.26% and a negative net margin of 1,237.92%. View Arbutus Biopharma's Earnings History.

When is Arbutus Biopharma's next earnings date?

Arbutus Biopharma is scheduled to release their next quarterly earnings announcement on Thursday, August 1st 2019. View Earnings Estimates for Arbutus Biopharma.

What price target have analysts set for ABUS?

5 Wall Street analysts have issued 1-year target prices for Arbutus Biopharma's stock. Their predictions range from $5.00 to $9.00. On average, they expect Arbutus Biopharma's stock price to reach $6.8333 in the next year. This suggests a possible upside of 257.8% from the stock's current price. View Analyst Price Targets for Arbutus Biopharma.

What is the consensus analysts' recommendation for Arbutus Biopharma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Arbutus Biopharma.

Has Arbutus Biopharma been receiving favorable news coverage?

Media coverage about ABUS stock has trended somewhat positive on Saturday, according to InfoTrie. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Arbutus Biopharma earned a news sentiment score of 1.6 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next few days.

Who are some of Arbutus Biopharma's key competitors?

What other stocks do shareholders of Arbutus Biopharma own?

Who are Arbutus Biopharma's key executives?

Arbutus Biopharma's management team includes the folowing people:
  • Dr. Mark Joseph Murray, Pres, CEO & Director (Age 70)
  • Mr. David C. Hastings, CFO & Chief Accounting Officer (Age 58)
  • Dr. Gaston Picchio Ph.D., Chief Devel. Officer (Age 56)
  • Dr. Michael J. Sofia, Chief Scientific Officer (Age 61)
  • Dr. Elizabeth Howard, Exec. VP, Gen. Counsel & Chief Compliance Officer (Age 65)

Who are Arbutus Biopharma's major shareholders?

Arbutus Biopharma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.07%), Bank of Montreal Can (1.72%), Morgan Stanley (1.70%), Bailard Inc. (0.41%), Alps Advisors Inc. (0.24%) and Oxford Asset Management LLP (0.13%). View Institutional Ownership Trends for Arbutus Biopharma.

Which major investors are selling Arbutus Biopharma stock?

ABUS stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, BlackRock Inc. and California State Teachers Retirement System. View Insider Buying and Selling for Arbutus Biopharma.

Which major investors are buying Arbutus Biopharma stock?

ABUS stock was bought by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP, Jacobs Levy Equity Management Inc., The Manufacturers Life Insurance Company , Wells Fargo & Company MN, Bailard Inc., Bank of Montreal Can, State of Wisconsin Investment Board and Jefferies Group LLC. View Insider Buying and Selling for Arbutus Biopharma.

How do I buy shares of Arbutus Biopharma?

Shares of ABUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arbutus Biopharma's stock price today?

One share of ABUS stock can currently be purchased for approximately $1.91.

How big of a company is Arbutus Biopharma?

Arbutus Biopharma has a market capitalization of $108.58 million and generates $5.90 million in revenue each year. The biopharmaceutical company earns $-57,060,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Arbutus Biopharma employs 79 workers across the globe.

What is Arbutus Biopharma's official website?

The official website for Arbutus Biopharma is http://www.arbutusbio.com/.

How can I contact Arbutus Biopharma?

Arbutus Biopharma's mailing address is 100-8900 GLENLYON PARKWAY, BURNABY A1, V5J 5J8. The biopharmaceutical company can be reached via phone at 604-419-3200 or via email at [email protected]


MarketBeat Community Rating for Arbutus Biopharma (NASDAQ ABUS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  338 (Vote Outperform)
Underperform Votes:  253 (Vote Underperform)
Total Votes:  591
MarketBeat's community ratings are surveys of what our community members think about Arbutus Biopharma and other stocks. Vote "Outperform" if you believe ABUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/25/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel